Insight Molecular DiagnosticsIMDX +4.10%49 Cash Ratio is 2.35 as of Mar. 2026, which is 3% below its 10-year median of 2.42. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 80.86% on this metric.
Insight Molecular Diagnostics has a Cash Ratio of 2.35. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Insight Molecular Diagnostics's Cash Ratio or its related term are showing as below:
IMDX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.37 Med: 2.42 Max: 12.47
Current: 2.35
During the past 13 years, Insight Molecular Diagnostics's highest Cash Ratio was 12.47. The lowest was 0.37. And the median was 2.42.
IMDX's Cash Ratio is ranked better than 80.86% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.97
vs IMDX: 2.35
Insight Molecular Diagnostics (NAS:IMDX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Insight Molecular Diagnostics Cash Ratio Related Terms
Insight Molecular Diagnostics Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a Cash Ratio of 2.35 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Insight Molecular Diagnostics and its competitors. This is near median its historical median of 2.42. Over the past decade, Insight Molecular Diagnostics' Cash Ratio has ranged from 0.37 to 12.47. According to the industry distribution chart, Insight Molecular Diagnostics ranks #40 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 19.1%.
Is Insight Molecular Diagnostics' Cash Ratio too high?
Insight Molecular Diagnostics' current Cash Ratio of 2.35 is near median its 10-year median of 2.42. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 12.47. The Medical Diagnostics & Research industry median Cash Ratio is 0.97. Insight Molecular Diagnostics' value of 2.35 is 142.3% above this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #40 out of 209 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Cash Ratio compare to XGN and BDSX?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #40 out of 209 companies for Cash Ratio. This places Insight Molecular Diagnostics in the top 19% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. Insight Molecular Diagnostics' value of 2.35 is 142.3% above this benchmark. Historically, Insight Molecular Diagnostics' own Cash Ratio has ranged from 0.37 to 12.47 over the past decade. While the company's 10-year median is 2.42 vs. the industry median of 0.97, Insight Molecular Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.97, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Cash Ratio of 2.35 is 142.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Cash Ratio is 2.35, which is near median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $5.07 — trading 305.6% above its estimated fair value. The current Cash Ratio is 2.35, which is near median its 10-year median of 2.42 and 142.3% above the Medical Diagnostics & Research industry median of 0.97. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Cash Ratio is 2.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.07 is trading 305.6% above its estimated GF Value™ of $1.25.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Cash Ratio: 2.35 (near median its 10-year median of 2.42)
GF Value™: $1.25 vs. price of $5.07 (305.6% above fair value)
Industry Position: 142.3% above the Medical Diagnostics & Research median (#40 of 209)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
